Lv61
1740 积分 2021-11-03 加入
Prevalence and Treatment of Diabetes in China, 2013-2018
20天前
已完结
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease
27天前
已完结
A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor
1个月前
已完结
A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
1个月前
已完结
持续葡萄糖监测基层临床应用专家共识（2025年）
1个月前
已完结
糖尿病周围神经病变是“对症治疗”还是“预防为主”更重要？
1个月前
已完结
基础胰岛素周制剂依柯胰岛素治疗2型糖尿病临床应用专家指导建议（2025版）
1个月前
已完结
Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study
2个月前
已完结
Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study
3个月前
已完结
Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes
3个月前
已完结
皖公网安备34019202002308
